A small, phase II, randomized, double blinded, placebo-controlled study to evaluate the impact of low doses of nilotinib in Alzheimer’s disease finds that it is safe and well-tolerated. The researchers, from Georgetown University Medical Center, say the drug should be tested in a larger study to further determine its safety and efficacy as a potential…
Tag: biomarkers
CRISPR Helps Identify New Biomarker For Alzheimer’s Disease
STIM1 protein expression decreases with the progression of neurodegeneration in Alzheimer’s disease, new research indicates. Conducted at the Institute of Molecular Pathology Biomarkers, University of Extremadura, in Badajoz, Spain, the study’s aim was to develop a model for studying Alzheimer’s disease (AD) of sporadic origin—in other words, AD that is not due to a hereditary…
New Brain Inflammation Biomarker In Early-stage Alzheimer's
A brain inflammation marker in patients at early asymptomatic stages of Alzheimer’s disease has been identified by researchers at Ludwig-Maximilians-University, the German Center for Neurodegenerative Diseases (DZNE), and the Institute for Stroke and Dementia Research (ISD) in Munich. This secreted marker molecule, which can be measured from cerebrospinal fluid taps, may provide clinicians with a…
Psychosis Biotypes Identified Using Brain-Based Biomarkers
Biological markers that make it possible to classify mental disorders with greater precision have been identified by a team of researchers led by faculty at the University of Georgia. The findings may one day lead to improved diagnostics and treatments for those suffering from mental illness. The advent of modern medical diagnostic tools has made…